Patients at increased CV risk due to the presence of 2 modifiable risk factors HTN & dyslipidemia; &/or chronic stable angina. Prevention of CV complications in hypertensive patients. 1st-line treatment of HTN & can be used as the sole agent to control BP in the majority of patients. Reduce the risk of fatal CHD & non-fatal MI, & to reduce the risk of stroke. Myocardial ischemia, whether due to fixed obstruction (stable angina) &/or vasospasm/vasoconstriction (Prinzmetal's or variant angina) of coronary vasculature. May be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. May be used alone or in combination w/ other anti-anginal drugs in patients w/ angina that is refractory to nitrates &/or adequate doses of β-blockers. Adjunct to diet for the treatment of patients w/ elevated total cholesterol, LDL-cholesterol, apolipoprotein B & triglycerides & to increase HDL-cholesterol in patients w/ primary hypercholesterolemia (heterozygous familial & nonfamilial hypercholesterolemia), combined (mixed) hyperlipidemia (Fredrickson Types IIa & IIb), elevated serum triglyceride levels (Fredrickson Type IV), & for patients w/ dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Reduction of total cholesterol & LDL-cholesterol in patients w/ homozygous familial hypercholesterolemia when response to diet & other nonpharmacological measures are inadequate. Reduce the risk of fatal CHD & non-fatal MI, stroke, revascularization procedures & angina pectoris in patients w/o clinically evident CV disease & w/ or w/o dyslipidemia, but w/ multiple risk factors for CHD eg, smoking, HTN, diabetes, low HDL-C, or a family history of early CHD. Reduce the risk of nonfatal MI, fatal & nonfatal stroke, revascularization procedures, hospitalization for CHF & angina in patients w/ clinically evident CHD. Adjunct to diet to reduce total-C, LDL-C, & apo B levels in boys & postmenarchal girls, 10-17 years, w/ heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL & there is a positive family history of premature CV disease or ≥2 other CVD risk factors.